Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova and dapagliflozin for liver fat content in type 2 diabetes
2014-003638-26Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Epanova + Farxiga with Placebo (2 arms). Primary endpoint: Change in liver fat content from baseline to week 12. Started Oct 2014; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic aciddapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2014-003638-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003638-26.